-
Your next patient is a 35-year-old mother of two who is experiencing ongoing heavy menstrual bleeding (menorrhagia). Recently remarried, she says she may want to have a child in the future with her new partner. What are your treatment options?
-
For years, the much talked-about male contraceptive pill has remained tantalizingly out of reach. What if the first contraceptive method to reach the commercial market relied on a nonhormonal approach instead?
-
When discussing spermicides with prospective users, family planning providers in the United States have only nonoxynol-9 (N-9) formulations in the contraception arsenal. What if there were other formulations added to the mix?
-
Research findings have suggested higher failure rates in oral contraceptive (OC) users who are heavy; however, new results from a retrospective analysis of Phase III efficacy data of a popular ethinyl estradiol/norgestimate formulation (Ortho Tri-Cyclen Lo, Ortho McNeil Pharmaceutical; Raritan, NJ) indicate that it is not associated with an increased risk of pregnancy in such women.
-
Unplanned pregnancies carry extra health risks for obese women. In a 2005 study, researchers found that overweight women (BMI 25-29.9) had increased risks of diabetes, hypertension, pre-eclampsia, and cesarean delivery, with even higher risks for obese women (BMI 30 and above).
-
In this case-control study, the authors matched 235 graduates of 3 medical schools who were disciplined by their respective medical boards between 1990 and 2003 with 469 control physicians who were matched based on graduation year and medical school.
-
One of the most recognized risk factors for the development of endometrial cancer is obesity. However, recent studies have suggested that this factor alone cannot fully account for all the risk associated with obesity.
-
In this New Zealand investigation, 257 premenopausal women undergoing hysterectomy were prospectively compared to 259 cohorts who did not have a hysterectomy.
-
Twenty-three patients are reported with osteonecrosis of the mandible or maxilla associated with bisphosphonate treatment.
-
The STAR Trial (Tamoxifen and Raloxifene); FDA Actions
